Gilead Sciences, Inc.
TLR-9 AGONISTS FOR MODULATION OF TUMOR MICROENVIRONMENT
Last updated:
Abstract:
A TLR-9 agonist for use in the treatment of a tumor disease, in particular of colon cancer, and for the modulation of the tumor microenvironment.
Status:
Application
Type:
Utility
Filling date:
31 Aug 2018
Issue date:
27 May 2021